# Dare Bioscience Inc. (DARE)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $23M  
**Price:** $2.03 (+1.50%)

> Dare Bioscience Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products in women's reproductive health. The company advances a portfolio of differentiated therapies aimed at contraception, fertility, and related conditions, prioritizing women's health and expanding treatment options. Key products in development include Ovaprene, a hormone-free monthly contraceptive ring, and Topical Sildenafil, a treatment for female sexual dysfunction. Operating within the health technology sector, specifically pharmaceuticals, Dare Bioscience Inc. engages in identifying, developing, and bringing innovative solutions to market that address unmet needs in women's health and well-being. Founded in 2005 and headquartered in San Diego, California, the company plays a role in advancing specialized therapies in the reproductive health market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1M | — | -$14M | -$13M | — |
| 2024 | $9,784 | — | -$23M | -$4M | — |
| 2023 | $3M | — | -$31M | -$30M | — |
| 2022 | $10M | — | -$31M | -$31M | — |
| 2021 | — | — | -$39M | -$39M | — |
| 2016 | $766,000 | — | -$630,591 | -$672,687 | — |
| 2014 | $80,000 | — | — | -$23M | — |
| 2013 | $6,000 | — | — | -$17M | — |
| 2012 | $625,000 | — | — | -$22M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $32M | $30M | $3M | $25M | — |
| 2024 | $22M | $28M | -$6M | $16M | — |
| 2023 | $21M | $26M | -$5M | $10M | — |
| 2022 | $44M | $33M | $11M | $35M | — |
| 2021 | $56M | $17M | $39M | $52M | — |
| 2016 | $44,614 | $755,235 | -$710,621 | $44,614 | — |
| 2014 | $53M | — | $45M | $51M | — |
| 2013 | $7M | — | -$94M | $5M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$10M | $385,278 | -$10M |
| 2024 | $5M | $573,046 | $5M |
| 2023 | -$39M | $629,430 | -$39M |
| 2022 | -$18M | $63,069 | -$18M |
| 2021 | -$29M | $14,524 | -$29M |
| 2020 | -$25M | $17,625 | -$25M |
| 2019 | -$13M | — | -$13M |
| 2018 | -$10M | $11,836 | -$10M |
| 2017 | -$3M | — | -$3M |

Source: [CompaniesByCap](https://companiesbycap.com/company/DARE)